Approaches to applying breast cancer risk prediction models in clinical practice

Community Oncology

Volumn 6, Issue 8, 2009, Pages

  Bellcross, Cecelia ^a,b  

^a Dean Health System   (United States)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST CANCER; CANCER RISK; CLINICAL PRACTICE; ENDOMETRIUM CANCER; FAMILY HISTORY; GENETIC RISK; HUMAN; PATIENT CARE; REVIEW; STROKE; UNSPECIFIED SIDE EFFECT;

EID: 70349399270     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70263-7     Document Type: Review

References (37)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001;358:1389-1399.
2. Parazzini F, La Vecchia C, Negri E, et al. Menstrual and reproductive factors and breast cancer in women with family history of the disease. Int J Cancer 1992;51:677-681.
3. McDivitt RW, Stevens JA, Lee NC, et al. Histologic types of benign breast disease and the risk for breast cancer. The Cancer and Steroid Hormone Study Group. Cancer 1992;69:1408-1414.
4. Hamajima N, Hirose K, Tajima K, et al. Alcohol, tobacco and breast cancercollaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 2002;87:1234-1245.
5. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-1059.
6. Vachon CM, van Gils CH, Sellers TA, et al. Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res 2007;9:217.
7. Santen RJ, Boyd NF, Chlebowski RT, et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer 2007;14:169-187.
8. Claus EB, Schildkraut JM, Thompson WD, et al. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318-2324.
9. Rubinstein WS. The genetics of breast cancer. In: Vogel VG, ed. Management of Patients at High Risk for Breast Cancer. Malden, MA: Blackwell Science, Inc.; 2001:19-55.
10. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. Oncogene 2006;25:5898-5905.
11. Pharoah PD, Antoniou AC, Easton DF, et al. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008;358:2796-2803.
12. Trepanier A, Ahrens M, McKinnon W, et al. Genetic cancer risk assessment and counseling: recommendations of the National Society of Genetic Counselors. J Genet Counsel 2004;13:83-114.
13. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886.
14. Rockhill B, Spiegelman D, Byrne C, et al. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001;93:358-366.
15. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. Cancer 1994;73:643-651.
16. van Asperen CJ, Jonker MA, Jacobi CE, et al. Risk estimation for healthy women from breast cancer families: new insights and new strategies. Cancer Epidemiol Biomarkers Prev 2004;13:87-93.
17. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:1111-1130.
18. Amir E, Evans DG, Shenton A, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 2003;40:807-814.
19. Jacobi CE, de Bock GH, Siegerink B, et al. Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat 2009;115:381-390.
20. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-151.
21. Wang J, Costantino JP, Tan-Chiu E, et al. Lower category benign breast disease and the risk of invasive breast cancer. J Natl Cancer Inst 2004;96:616-620.
22. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353:229-237.
23. Tice JA, Cummings SR, Smith-Bind- man R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008;148:337-347.
24. Collins LC, Baer HJ, Tamimi RM, et al. The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study. Cancer 2006;107:1240-1247.
25. Berry DA, Iversen ES Jr, Gudbjarts- son DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.[see comment]. J Clin Oncol 2002;20:2701-2712.
26. Antoniou AC, Pharoah PP, Smith P, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancer.[see comment]. Br J Cancer 2004;91:1580-1590.
27. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-1490.
28. U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005;143:355-361.
29. Buxton JA, Bottorff JL, Balneaves LG, et al. Women's perceptions of breast cancer risk: are they accurate? Can J Public Health 2003;94:422-426.
30. Smith BL, Gadd MA, Lawler C, et al. Perception of breast cancer risk among women in breast center and primary care settings: correlation with age and family history of breast cancer. Surgery 1996;120:297-303.
31. Black WC, Nease RF Jr, Tosteson AN. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst 1995;87:720-731.
32. Fagerlin A, Zikmund-Fisher BJ, Ubel PA. If I'm better than average, than I'm ok?: comparative information influences beliefs about risk and benefits. Patient Educ Counsel 2007;69:140-144.
33. Calvocoressi L. Kasl SV, Lee CH, et al. A prospective study of perceived susceptibility to breast cancer and nonadherence to mammography screening guidelines in African American and white women ages 40 to 79 years. Cancer Epidemiol Biomarkers Prev 2004;13:2096-2105.
34. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89.
35. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-1388.
36. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-1846.
37. Burke W, Culver JO, Bowen D, et al. Genetic counseling for women with an intermediate family history of breast cancer. Am J Med Genet 2000;90:361-368.